VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Interim results for BCMA T-cell engager CC-93269 in RRMM

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, presents the interim results of the first clinical study of the bispecific BCMA/CD3 T-cell engager CC-93269 in patients with relapsed/refractory multiple myeloma (CC-93269-MM-001; NCT03486067). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter